Zimmer Biomet (NYSE:ZBH) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Zimmer Biomet (NYSE:ZBH) from a buy rating to a hold rating in a research note published on Sunday morning.

Several other analysts also recently commented on the stock. Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a report on Wednesday, November 5th. Rothschild & Co Redburn started coverage on shares of Zimmer Biomet in a research report on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective for the company. Evercore ISI reduced their price objective on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a report on Tuesday, October 7th. Redburn Partners set a $130.00 target price on Zimmer Biomet in a research note on Thursday, September 18th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $100.00 price target (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $109.00.

Zimmer Biomet Stock Up 0.5%

ZBH stock opened at $89.10 on Friday. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $17.66 billion, a PE ratio of 21.68, a PEG ratio of 2.29 and a beta of 0.67. Zimmer Biomet has a 1-year low of $85.33 and a 1-year high of $114.44. The business’s 50 day simple moving average is $97.95 and its 200 day simple moving average is $96.84.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter last year, the firm posted $1.74 EPS. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is 23.76%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.39% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

A number of large investors have recently bought and sold shares of the company. Key Financial Inc lifted its holdings in shares of Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. lifted its stake in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 149 shares in the last quarter. Root Financial Partners LLC bought a new position in shares of Zimmer Biomet in the 3rd quarter valued at $31,000. Finally, Accent Capital Management LLC bought a new position in shares of Zimmer Biomet in the 1st quarter valued at $35,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.